Co-Diagnostics, Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022

Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will present at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022. The event takes place from November 29 to December 1, 2022, in New York City. CEO Dwight Egan and President Dr. Kirk Ririe will discuss recent advancements and the upcoming Co-Dx PCR diagnostic platform. The presentation will be available online at 11:30 AM Eastern Time on the day of the event. Additionally, one-on-one meetings for institutional investors will be coordinated with Company or Piper Sandler representatives.

News Market Reaction – CODX

+0.67%

+0.67% Session move

In the trading session that priced this news, CODX gained 0.67%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, Nov. 30, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting on December 1, 2022, at the Piper Sandler 34^th Annual Healthcare Conference, held November 29-December 31, 2022, in New York City, New York.

Dwight Egan, Company CEO, and Dr. Kirk Ririe, President of the Company's subsidiary, will be conducting a presentation discussing recent and expected Company progress along with its forthcoming Co-Dx PCR diagnostic platform. A copy of the presentation can be accessed through the Events and Webcasts section of the Co-Diagnostics website on December 1, 2022, at 11:30 AM Eastern Time. 

The Company will also be participating in one-on-one meetings for institutional investors and industry professionals who have registered for the event, which can be arranged with Company or Piper Sandler representatives.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-present-at-the-piper-sandler-34th-annual-healthcare-conference-on-december-1-2022-301690328.html

SOURCE Co-Diagnostics

FAQ

What is Co-Diagnostics presenting at the Piper Sandler Conference?

Co-Diagnostics will present on recent advancements and their upcoming Co-Dx PCR diagnostic platform.

When is Co-Diagnostics scheduled to present?

Co-Diagnostics is scheduled to present on December 1, 2022, at 11:30 AM Eastern Time.

Where is the Piper Sandler 34th Annual Healthcare Conference held?

The conference is held in New York City from November 29 to December 1, 2022.

Who will represent Co-Diagnostics at the conference?

CEO Dwight Egan and President Dr. Kirk Ririe will represent Co-Diagnostics.

How can investors arrange one-on-one meetings with Co-Diagnostics?

Investors can arrange one-on-one meetings with Co-Diagnostics or Piper Sandler representatives.